Drug Developer Opts for RWE Model to Study Psychedelic Therapies
Albert Labs, a UK-based R&D company, is exploring a new way to fast track how quickly patients can access psychedelic therapies by leveraging Real World Evidence (“RWE”) while developing the medicines needed to manage a variety of mental health ailments. While the current range of pharmaceutical medicines for mental health issues is diverse, an increasing number of patients aren’t responding to these conventional treatments. Additionally, some mental health issues seem to have no current treatment modality indicated for them. A case in point is cancer-induced anxiety, which can lower treatment compliance rates and even drive up the number of suicides…